格列齐特缓释片对2型糖尿病患者血浆纤溶酶原激活物抑制剂-1的影响  

Effect of sustained-release gliclazide on PAI-1 in patients with type 2 diabetes mellitus

作　　者：曹雪霞[1] 尚静[2] 杨光燃[3] 

机构地区：[1]首都医科大学宣武医院内分泌科,北京100053 [2]首都医科大学宣武医院检验科,北京100053 [3]首都医科大学附属北京同仁医院内分泌科,北京100730

出　　处：《中国新药杂志》2008年第12期1070-1072,1077,共4页Chinese Journal of New Drugs

摘　　要：目的:比较口服格列齐特缓释片和格列本脲片对2型糖尿病患者血浆纤溶酶原激活物抑制剂-1(PAI-1)的影响。方法:58例诊断明确的2型糖尿病患者随机分成格列齐特缓释片组30例和格列本脲组28例。于治疗前和治疗3个月后,分别测血压、血糖、糖化血红蛋白(HbA1c)、血脂和PAI-1的水平。结果:与治疗前比较,格列齐特缓释片组PAI-1的水平下降约9.3 ng.mL-1(P<0.01);而格列本脲组下降不足1.0ng.mL-1(P>0.05)。结论:与格列本脲相比,格列齐特缓释片能有效降低2型糖尿病患者的血PAI-1的水平,有助于保护内皮功能,预防大血管和微血管的并发症。Objective： To compare the effects of sustained-release gliclazide and glibenclamide on plas- minogen activator inhibitor-1 （PAI-1） in type 2 diabetic patients. Methods： Totally 58 patients were randomly di- vided into two groups, and treated with either sustained-release gliclazide （n = 30） or glibenclamide （n = 28）. At the baseline and the end of 3 month treatment, blood glucose, HbAlc, serum lipid and PAI-1 were measured. Resuits： Compared with the baseline values, PAI-1 was reduced by 9.3 ng.mL -~ in sustained-release gliclazide group （P 〈0.0! ） 3 months after the treatment, but only reduced by 1.0 ng·mL -1 in glibenclamide group （P 〉 0.05 ）. Conclusion： Sustained-release gliclazide in once daily regimen reduces PAI-1 more effectively than glibenclamide in type 2 diabetes, which may be beneficial for protecting endothelial function, and preventing the microvascular and macrovascular complications.

关 键 词：2型糖尿病 格列齐特缓释片 格列本脲 血浆纤溶酶原激活物抑制剂-1 

分 类 号：R977.15[医药卫生—药品] R969.4[医药卫生—药学]